Business case: Investing in Production of High-Quality Oxytocin for Low-Resource Settings 26-03-2015
This report by the Reproductive Health Supplies Coalition provides the business case for investing in high-quality magnesium sulfate in low-resource settings. The oxytocin business case is one of a three-part series focused on maternal health products that also includes business cases on the markets for misoprostol and magnesium sulfate. Together, these three maternal health drugs are very effective at preventing maternal
deaths, but there are problems with ensuring a reliable supply of high-quality, affordable products for countries to procure.